

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## CCL21 RABBIT PAB

Cat.#: S216402

Product Name: Anti-CCL21 Rabbit Polyclonal Antibody

Synonyms: ECL; SLC; CKb9; TCA4; 6Ckine; SCYA21

UNIPROT ID: 000585 (Gene Accession - BC027918)

**Background:** This antimicrobial gene is one of several CC cytokine genes clustered on the p-arm of chromosome 9. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. Similar to other chemokines the protein encoded by this gene inhibits hemopoiesis and stimulates chemotaxis. This protein is chemotactic in vitro for thymocytes and activated T cells, but not for B cells, macrophages, or neutrophils. The cytokine encoded by this gene may also play a role in mediating homing of lymphocytes to secondary lymphoid organs. It is a high affinity functional ligand for chemokine receptor 7 that is expressed on T and B lymphocytes and a known receptor for another member of the cytokine family (small inducible cytokine A19). [provided by RefSeq, Sep 2014]

Immunogen: Fusion protein of human CCL21

Applications: ELISA, IHC

Recommended Dilutions: IHC: 50-200; ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human

**Constituents:** PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Immunology

**Storage & Shipping:** Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human prostate cancer tissue using 216402(CCL21 Antibody) at a dilution of 1/60(Secreted). In comparision with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with the fusion protein and then with 216402(Anti-CCL21 Antibody) at dilution 1/60.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010